Business Context and Reporting Period
This Form 8-K Current Report was filed by MIMEDX GROUP, INC. on July 5, 2023. The filing reports a significant change in executive leadership, specifically the appointment of a new Chief Financial Officer (CFO) and the resignation of the incumbent CFO, effective July 5, 2023.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
Material Changes
- Executive Departure: Peter Carlson submitted his resignation as Chief Financial Officer, effective July 5, 2023.
- Executive Appointment: Doug Rice was appointed as Chief Financial Officer, effective July 5, 2023.
- Compensation Structure: The Company has entered into new employment and retention agreements with Mr. Rice, establishing a new compensation framework for the CFO role.
Guidance, Outlook, and Management Commentary
The filing details the specific compensation package for the new CFO, Doug Rice, which includes:
- Base Salary: $540,000 annually.
- Cash Bonus: Target of 60% of base salary under the Management Incentive Plan.
- Sign-on Equity Grants:
- 162,000 Performance Stock Units (PSUs) vesting over a three-year period ending December 31, 2025.
- 97,200 Restricted Stock Units (RSUs) vesting annually over three years.
- 94,000 Stock Options vesting annually over four years.
- Future Awards: Eligibility for annual awards anticipated to equal 200% of base salary, vesting over three years.
- Severance and Change in Control: Lump sum benefits of 1.25x base salary and target bonus for no-cause/good-reason termination, increasing to 1.5x within one year of a change in control. Benefit continuation or cash equivalents are provided for 15 to 18 months depending on the scenario.
The filing notes that Mr. Rice previously served as CFO of Orthofix Medical Inc. until January 2023. No specific financial guidance or operational outlook is provided in this document.
Investor Verification Checklist
- Verify the exact vesting schedules and performance conditions for the 162,000 PSUs granted to Doug Rice.
- Review the full text of the Key Employee Retention and Restrictive Covenant Agreement (Exhibit 10.2) to understand specific "Good Reason" and "Change in Control" definitions.
- Confirm the impact of the CFO transition on the Company's upcoming financial reporting cycles.
- Check for any subsequent filings regarding the departure of Peter Carlson to ensure no undisclosed liabilities or disputes exist.